ライフサイエンスコーパス: osteolytic

1 LNCaP bone tumors were both osteoblastic and osteolytic.

2 derately osteoblastic LM8 (P < 0.05) and the osteolytic 143B (P < 0.01) cell line-derived tumors.

3 that give rise to advanced bone cancer pain, osteolytic 2472 sarcoma cells or media were injected int

4 pain, we used an in vivo model where murine osteolytic 2472 sarcoma cells were injected and confined

5 The majority of the osteolytic (72; 93.5%) and mixed-pattern lesions (nine;

6 The 146 lesions were classified as osteolytic (77), osteoblastic (41), mixed-pattern (11),

7 bers of MF OCs are increased, their impaired osteolytic activity distorts bone remodeling and contrib

8 NKL) with osteoprotegerin (OPG) prevents the osteolytic activity of CaP and its ability to establish

9 expression of target genes that mediate the osteolytic activity of metastatic breast cancer cells.

10 NKL/OPG) ratio as the primary determinant of osteolytic activity, while a low RANKL/OPG ratio is ofte

11 eoblastic activity, but had no effect on its osteolytic activity.

12 aled the mixed bone lesions, comprising both osteolytic and osteoblastic elements.

13 ese effects were enhanced in the presence of osteolytic and osteoblastic factors such as RANKL (recep

14 s can be useful tools in characterizing pure osteolytic and osteoblastic lesions induced by human pro

15 pressing LNCaP cells (LNCaP-PDGF-D) revealed osteolytic and osteoblastic responses similar to those o

16 tably, the model revealed distinct phases of osteolytic and osteogenic activity, a critical role for

17 We review the biology of osteolytic and osteosclerotic lesions, with a focus on e

18 ce for close interplay between inflammatory, osteolytic and tumor cell-driven events in the bone-tumo

19 inally assess the formation of osteoblastic, osteolytic, and mixed lesions formed by human prostate c

20 ppears to be the centerpiece of inflammatory-osteolytic arthritis and direct inhibition of this trans

21 Interestingly, ATL cells overexpressed the osteolytic-associated genes-Wnt5a, PTHLH, and RANKL.

22 teum, similar to that found in patients with osteolytic bone cancer.

23 The osteolytic bone destruction associated with breast cance

24 a tumor-bone co-culture system and enhances osteolytic bone destruction in mice, but also inhibits o

25 a support a model in which tumor cells cause osteolytic bone destruction independently of the RANK li

26 al for the development of metastasis-related osteolytic bone destruction.

27 ould decrease PTHrP expression and therefore osteolytic bone destruction.

28 d with human metastatic bone disease such as osteolytic bone destruction.

29 a key role in the pathogenesis of MM-related osteolytic bone disease (OBD).

30 factor, osteoprotegerin, were protected from osteolytic bone disease and developed fewer soft-tissue

31 masome-independent production of IL-1beta in osteolytic bone disease and identify PSTPIP2 as a negati

32 roid hormone-related peptide (PTHrP), namely osteolytic bone disease associated with breast cancer an

33 y multiple myeloma (MM) cells contributes to osteolytic bone disease by inhibiting the differentiatio

34 y play a critical role in the development of osteolytic bone disease in multiple myeloma and that tar

35 Il1r and Il1beta, but not Il1alpha, rescued osteolytic bone disease in mutant mice.

36 ized the osteoimmunological underpinnings of osteolytic bone disease in Pstpip2(cmo) mice.

37 Osteolytic bone disease is a major cause of morbidity in

38 del, treatment with NB-DNJ markedly improved osteolytic bone disease symptoms.

39 ted with tumor growth within bone marrow and osteolytic bone disease.

40 can promote myeloma growth and survival and osteolytic bone disease.

41 oma (MM), particularly in the development of osteolytic bone disease.

42 nists for the treatment of MM and associated osteolytic bone disease.

43 e marrow, elevated serum immunoglobulin, and osteolytic bone disease.

44 onment in myeloma counteracts development of osteolytic bone disease.

45 ls in the bone marrow and the development of osteolytic bone disease.

46 multiple myeloma progression and associated osteolytic bone disease.

47 on of GSLs in osteoclast (OC) activation and osteolytic bone diseases in malignancies such as the pla

48 identify increased numbers of osteoclasts in osteolytic bone diseases such as osteolytic bone metasta

49 new therapeutic approaches to combat various osteolytic bone diseases.

50 ie2 activity in vivo significantly inhibited osteolytic bone invasion and tumor growth in a mammary t

51 w function of Tie2 in osteoclastogenesis and osteolytic bone invasion of breast cancer.

52 ain and bone metastases as well as decreased osteolytic bone lesion area and reduced numbers of osteo

53 f symptomatic MM is a well-demarcated, focal osteolytic bone lesion.

54 Multiple myeloma (MM) is characterized by osteolytic bone lesions (OBL) that arise as a consequenc

55 splacement of hematopoiesis and formation of osteolytic bone lesions also known as myeloma bone disea

56 major contributing factor to the increase in osteolytic bone lesions and hypercalcemia found in ATL p

57 read dissemination of tumor cells leading to osteolytic bone lesions and liver metastases, common sit

58 t increased IL-1 signaling can cause aseptic osteolytic bone lesions and that the absence of IL-10 si

59 acid phosphatase to confirm the presence of osteolytic bone lesions and the presence of osteoclasts,

60 andibular alveolar processes for presence of osteolytic bone lesions around causative teeth roots and

61 day) significantly reduced the occurrence of osteolytic bone lesions in myeloma-bearing mice.

62 sk of skeletal complications associated with osteolytic bone lesions in patients with breast cancer a

63 r an effective therapeutic approach to treat osteolytic bone lesions in patients with myeloma.

64 Strong TGF-beta signaling in osteolytic bone lesions is suppressed directly by geneti

65 timyeloma therapy, regardless of presence of osteolytic bone lesions on conventional radiography.

66 Multiple myeloma (MM) is characterized by osteolytic bone lesions with uncoupled bone remodeling.

67 prevented myeloma-induced bone loss, reduced osteolytic bone lesions, and increased fracture resistan

68 Specifically, osteolytic bone lesions, where bone is destroyed, lead t

69 Breast cancer (BCa) bone metastases cause osteolytic bone lesions, which result from the interacti

70 E suppressed bone colonization and decreased osteolytic bone lesions.

71 oclast formation, and radiologic evidence of osteolytic bone lesions.

72 t was expressed in two of three specimens of osteolytic bone metastases (P=0.0119).

73 e that Smad4 contributes to the formation of osteolytic bone metastases and is essential for the indu

74 u-RGD has the potential to effectively image osteolytic bone metastases and monitor the physiologic c

75 (RGDyK) ((64)Cu-RGD) as an imaging agent for osteolytic bone metastases and their associated inflamma

76 ed, inhibited the progression of established osteolytic bone metastases as assessed by radiographic a

77 mor inoculation prevented the development of osteolytic bone metastases compared with vehicle.

78 cer cells may be vital to the development of osteolytic bone metastases in patients with breast cance

79 usly developed hypercalcemia, high-frequency osteolytic bone metastases, and enhanced osteoclast acti

80 y promoting hypercalcemia, tumor growth, and osteolytic bone metastases, but it is not known how PTHr

81 east cancer cells, which consistently formed osteolytic bone metastases, induced osteosclerotic lesio

82 eature of our findings was the occurrence of osteolytic bone metastases, which are prominent in human

83 d that seven different mouse models of human osteolytic bone metastases-representing breast, lung and

84 THrP-neutralizing antibody greatly decreased osteolytic bone metastases.

85 tases, induced osteosclerotic lesions in the osteolytic bone metastases.

86 the use of bisphosphonates in patients with osteolytic bone metastases.

87 eoclasts in osteolytic bone diseases such as osteolytic bone metastasis and inflammatory osteolysis.

88 animal model of high-penetrance spontaneous osteolytic bone metastasis and underscore the critical r

89 EGF receptor (EGFR) inhibitors block osteolytic bone metastasis by targeting EGFR signaling i

90 into the left cardiac ventricle resulted in osteolytic bone metastasis in 74% of beta3+/+ mice by 14

91 rolling not only tumor angiogenesis but also osteolytic bone metastasis in breast cancer.

92 ious carcinomas such as breast cancer, where osteolytic bone metastasis is associated with increased

93 We further observed that osteolytic bone metastasis led to a decrease in HA nanoc

94 rget of NF-kappaB and found that it mediates osteolytic bone metastasis of breast cancer by stimulati

95 ppaB (NF-kappaB) plays a crucial role in the osteolytic bone metastasis of breast cancer by stimulati

96 to evaluate the mechanism of MMP13-dependent osteolytic bone metastasis revealed that MMP13-ASO treat

97 over a new and specific role of NF-kappaB in osteolytic bone metastasis through GM-CSF induction, sug

98 id hormone-related protein (PTHrP), enhanced osteolytic bone metastasis, and decreased survival.

99 al for the bone resorption characteristic of osteolytic bone metastasis.

100 ting tumor-stromal interactions that promote osteolytic bone metastasis.

101 ncer and implicate Rho-TGF-beta crosstalk in osteolytic bone metastasis.

102 ivo inhibits osteoclast activity and reduces osteolytic bone metastasis.

103 wed that they have the ability to reduce the osteolytic bone resorption associated with multiple myel

104 g DKK1 activity in myelomatous bones reduces osteolytic bone resorption, increases bone formation, an

105 Wu et al. identify MAOA as a key mediator of osteolytic bone responses that involve complex paracrine

106 or cells regulates processes associated with osteolytic bone tumor burden, we stably infected the bon

107 a unique expression signature that promotes osteolytic breast cancer bone metastasis and that inhibi

108 in immune-compromised animals bearing human osteolytic cancers.

109 Using a mouse model that mimics osteolytic changes associated with breast cancer-induced

110 CT revealed osteolytic changes in 41 (31%) and osteoblastic changes

111 PTHLH), leading to osteoclast maturation for osteolytic colonization.

112 ls perpetuate the inflammatory response, the osteolytic component of this disease is a direct result

113 may block TGF-beta propagation of a vicious osteolytic cycle in this MDA-MB-231 model of bone metast

114 sequently, pDC and CD4(+) T cells, producing osteolytic cytokines, increased with tumor burden, causi

115 duce a profound decrease in tumor burden and osteolytic damage in the murine 5TGM1 model of MM bone d

116 1beta expression precedes the development of osteolytic damage in young Pstpip2(cmo) mice, and geneti

117 round also demonstrated striking spontaneous osteolytic destruction of distal phalanges.

118 myeloma cells also reduced the formation of osteolytic disease in vivo after intratibial engraftment

119 mechanism by which Runx2 contributes to the osteolytic disease induced by MDA-MB-231 cells, we inves

120 ion of factors involved in the generation of osteolytic disease remain elusive.

121 ivin A levels were found in MM patients with osteolytic disease.

122 one-resorbing factors (PTHrP, IL8) promoting osteolytic disease.

123 2 short hairpin RNA inhibition prevented the osteolytic disease.

124 s and the bone microenvironment that lead to osteolytic disease.

125 pathway as a potential therapeutic target in osteolytic disease.

126 Osteolytic diseases, including rheumatoid arthritis, ost

127 pment of small-molecule therapeutics against osteolytic diseases.

128 ontic disease and other inflammation-related osteolytic diseases.

129 heumatoid arthritis, osteoporosis, and other osteolytic disorders.

130 rP, consistent with its previously described osteolytic effects in metastatic bone disease, can also

131 HCS mutation sensitizes the skeleton to the osteolytic effects of tumor necrosis factor alpha (TNFal

132 blished KLF4 null bone tumors inhibits their osteolytic effects, preventing bone fractures and induci

133 To determine whether the osteolytic factor parathyroid hormone-related protein (P

134 there is an increased expression of the pro-osteolytic factor termed receptor activator of nuclear f

135 ich in turn increases secretion of important osteolytic factors such as parathyroid hormone-related p

136 one-invasive oral SCC (OSCC) derived from an osteolytic feline OSCC.

137 C3H mice were injected with osteolytic fibrosarcoma cells in and around the calcaneu

138 Unilateral injection of osteolytic fibrosarcoma cells into and around the calcan

139 When tumors formed after injection of osteolytic fibrosarcoma cells into the calcaneus bone of

140 decreased OC numbers or impairment in their osteolytic function affects the development of osteoscle

141 s significantly reduced, indicating impaired osteolytic function.

142 se-directed processing of PTHrP disables the osteolytic functions of the mature hormone to promote os

143 x polymicrobial biofilm-induced inflammatory osteolytic gingival infection that results in orofacial

144 his study, we report that DKK-1 knockdown in osteolytic human PCa cells unexpectedly delays the devel

145 anism for modulating osteoclast signaling in osteolytic inflammatory disease.

146 Therapies to reverse tissue damage from osteolytic inflammatory diseases are limited by the inab

147 eering approach for the treatment of chronic osteolytic inflammatory diseases.

148 In a PC-3M-luc cell-induced osteolytic intraosseous model of prostate cancer, these

149 ss of Notch3 in osteoblastic tumors enhanced osteolytic lesion area and decreased osteoblastogensis.

150 Notch3 (NICD3) in osteolytic tumors reduced osteolytic lesion area and enhanced osteoblastogenesis,

151 ue involvement, presence of an abscess or an osteolytic lesion around causative tooth.

152 mechanisms of inhibiting myeloma growth and osteolytic lesion development.

153 r interactions governing the early events of osteolytic lesion formation are currently unclear.

154 tumours or systemic delivery of LOX leads to osteolytic lesion formation whereas silencing or inhibit

155 issemination in the bone marrow and enhanced osteolytic lesion formation, irrespective of HIF-1 Conve

156 the progression of soft tissue necrosis and osteolytic lesion formation.

157 er cells in the bone marrow and tumor-driven osteolytic lesion formation.

158 tion of LOX activity abrogates tumour-driven osteolytic lesion formation.

159 Infection of the dental pulp leads to an osteolytic lesion that results from a polymicrobial infe

160 ctures (45 [5%] vs 66 [7%]; p=0.04), and new osteolytic lesions (46 [5%] vs 95 [10%]; p<0.0001).

161 After treatment, 58 osteolytic lesions (80.5%) became [(18)F]FDG negative an

162 es that produce osteoblastic (MDA PCa 2b) or osteolytic lesions (PC-3).

163 CCR1 activation leads to the formation of osteolytic lesions and facilitates tumor growth.

164 g modality, its low sensitivity in detecting osteolytic lesions and inability to evaluate response to

165 toma cells recruited osteoclasts to generate osteolytic lesions and invade the bone matrix.

166 use model of bone metastasis, A77636 reduced osteolytic lesions and prevented mechanical weakening of

167 progeria-like disease phenotypes, including osteolytic lesions and rib fractures, osteoporosis, slow

168 Osteolytic lesions are a painful consequence of metastas

169 s that these compounds reduce PTHrP-mediated osteolytic lesions associated with metastatic human brea

170 , our findings suggest a novel mechanism for osteolytic lesions caused by cancer cells metastasizing

171 treatment completely prevented radiographic osteolytic lesions caused by human MDA-MB-231 breast can

172 l analysis at weekly intervals revealed that osteolytic lesions developed in the control tibias by 2

173 Anti-Wnt5a therapy may prevent or reduce osteolytic lesions found in ATL patients and improve the

174 Multiple myeloma is incurable once osteolytic lesions have seeded at skeletal sites, but fa

175 s may correlate with a propensity to develop osteolytic lesions in arthritis.

176 pose tissue, micrognathia, osteoporosis, and osteolytic lesions in bone.

177 reast cancer cells can prevent production of osteolytic lesions in bone.

178 lopecia, micrognathia, dental abnormalities, osteolytic lesions in bones, and osteoporosis, which are

179 at MMP-13 is critical for the development of osteolytic lesions in MM and that targeting the MMP-13 p

180 activity of osteoblasts (OBs) contributes to osteolytic lesions in multiple myeloma (MM).

181 very effective in limiting the formation of osteolytic lesions in PC-3 implanted tibias by inhibitin

182 Osteolytic lesions in the ribs led to spontaneous bone f

183 on of DKK1 by MM cells likely contributes to osteolytic lesions in this disease by inhibiting Wnt sig

184 n several human cancer cell lines that cause osteolytic lesions in vivo and produce PTHrP (MDA-MB-231

185 ort that human neuroblastoma cells that form osteolytic lesions in vivo do not produce osteoclast-act

186 tumor cells abolishes their ability to form osteolytic lesions in vivo.

187 n osteoblastic reaction in vitro and induced osteolytic lesions in vivo.

188 bone scans have sensitivity limitations for osteolytic lesions manifested in MM.

189 veloped hypercalcemia and significantly more osteolytic lesions than mice bearing CHO/EV tumors, with

190 a cells in the bone marrow induces localized osteolytic lesions that rarely heal due to increased bon

191 66 as a key oncogenic driver in PCa, causing osteolytic lesions through upstream epigenetic regulatio

192 ith established bone metastases, the size of osteolytic lesions was significantly reduced after 4 wee

193 osteolysis in mice receiving control cells, osteolytic lesions were significantly reduced following

194 Osteolytic lesions were successfully quantified using sm

195 metastasis produced detectable, progressive osteolytic lesions within 3 weeks of intracardiac inject

196 those cells with increased IGF-IR form both osteolytic lesions within the tibiae and secondary tumor

197 evented splenomegaly, limited development of osteolytic lesions, and concomitantly reduced tumor grow

198 turn a suppressor of osteoclastic activity, osteolytic lesions, and disease burden in a preclinical

199 correlated with markers of bone resorption, osteolytic lesions, and markers of disease activity.

200 r survival, a smaller tumor burden, and less osteolytic lesions, as compared with mice bearing contro

201 C4-2B's ability to induce mixed osteoblastic/osteolytic lesions, C4-2B cells were stably transfected

202 tumor primarily metastasizes to bone to form osteolytic lesions, causing severe pain and pathological

203 In cancer-induced osteolytic lesions, cleavage of receptor activator of nu

204 geting osteoclasts, which are upregulated in osteolytic lesions, may facilitate earlier follow-up in

205 acquired immune response could contribute to osteolytic lesions, we injected the periodontal pathogen

206 The osteolytic lesions, which develop usually in the long bo

207 frequently metastasize to bone, resulting in osteolytic lesions, yet the underlying mechanisms are po

208 and B-symptoms and was found to have diffuse osteolytic lesions.

209 ssion, radiation or surgery to bone, and new osteolytic lesions.

210 and decrease the progression of established osteolytic lesions.

211 mall group of Tax(+) animals presenting with osteolytic lesions.

212 nificantly prevented the formation of severe osteolytic lesions.

213 ant in the resulting suppression of skeletal osteolytic lesions.

214 cell line, C4-2B, induces mixed osteoblastic/osteolytic lesions.

215 te, significantly delayed the progression of osteolytic lesions.

216 alyses to identify molecular determinants of osteolytic lesions.

217 ue associated with progressive periarticular osteolytic lesions.

218 insipidus, bilateral ear discharge, and new osteolytic lesions.

219 with metastatic breast cancer who have known osteolytic lesions.

220 n myeloma cells inhibited the development of osteolytic lesions.

221 essential for the formation of premetastatic osteolytic lesions.

222 ne among those increased in MM patients with osteolytic lesions.

223 s more Notch3, than tumor cells that produce osteolytic lesions.

224 ecrete osteoclastogenic factors that promote osteolytic lesions; however, the identity of these facto

225 MMP-7 and MMP-9 null mice were injected with osteolytic luciferase-tagged mammary tumor cell lines.

226 Ewing sarcoma, an osteolytic malignancy that mainly affects children and y

227 in level is elevated in multiple myeloma, an osteolytic malignancy, where it might serve as predictiv

228 s no effective treatment for HTLV-1, and the osteolytic mechanisms are not fully understood.

229 n tyrosine phosphorylation induced 74% fewer osteolytic metastases as compared with the control group

230 Breast cancer commonly causes osteolytic metastases in bone, a process that is depende

231 one US and 12 European patients with painful osteolytic metastases involving bone were treated with i

232 RF ablation of painful osteolytic metastases is safe, and the relief of pain is

233 RFA of painful osteolytic metastases provides significant pain relief f

234 sms responsible for osteoclast activation in osteolytic metastases should lead to development of nove

235 detection of predominantly osteoblastic and osteolytic metastases were determined by using CT as the

236 carcinoma (RCC) patients often present with osteolytic metastases, we aimed to investigate serum scl

237 environment, leading to the establishment of osteolytic metastases.

238 ders such as osteoporosis and contributes to osteolytic metastases.

239 cificity of 92% (35 of 38) for predominantly osteolytic metastases.

240 treatment of hypercalcemia of malignancy and osteolytic metastases.

241 ignificantly reduces skeletal morbidity from osteolytic metastases.

242 ificity of 100% (38 of 38) for predominantly osteolytic metastases.

243 rapeutic targets to block progression toward osteolytic metastases.

244 ents with carcinoma of the gall bladder with osteolytic metastasis (stage 4).

245 ths, 12 adult patients with a single painful osteolytic metastasis in whom radiation therapy or chemo

246 mportant regulator of TGF-beta responses and osteolytic metastasis of breast cancer cells.

247 with patient matched visceral metastases or osteolytic metastasis samples.

248 is recommended in women with pain caused by osteolytic metastasis to relieve pain when used concurre

249 their role in tumor-bone interaction during osteolytic metastasis.

250 iation is crucial for improving treatment of osteolytic metastasis.

251 MGUS and suggest that cytokines elevated in osteolytic myeloma also may be associated with bone loss

252 one lesions in cervical cancer seem to be of osteolytic nature.

253 acilitate earlier follow-up in patients with osteolytic or mixed bone metastases.

254 Biofilm-induced inflammatory osteolytic oral infections, such as periodontitis and pe

255 es is problematic because the lesions can be osteolytic, osteoblastic, or mixed, and imaging modaliti

256 pletely prevented the establishment of mixed osteolytic/osteoblastic tibial tumors, as were observed

257 masked Wnt-mediated osteoblastic activity in osteolytic PC-3 cells, the cells were stably transfected

258 ted tumor formation in the bone, both in the osteolytic PC3 and osteoblastic/osteoclastic mixed C4-2B

259 nol-soluble modulins as aureolysin-degraded, osteolytic peptides that trigger osteoblast cell death a

260 differentiation in an otherwise predominant osteolytic phenomenon.

261 lls for bone and their tendency to induce an osteolytic phenotype are a result of interactions betwee

262 for the genomic instability, as well as the osteolytic phenotype of GCTB.

263 implicated in causing erosive arthritis, the osteolytic phenotypes of multiple myeloma and metastatic

264 ression was higher in cell lines with higher osteolytic potential in vivo.

265 also induces a transcriptional shift from an osteolytic program in KLF4 null cells to an osteogenic p

266 These mutations block the invasive and osteolytic properties of MDA-MB-231 breast cancer cells

267 Overexpression of p45-sErbB3 in the osteolytic prostate cancer cell line PC-3 converted its

268 lization (osteopenia) is coupled to enhanced osteolytic resorption in En1 mutants.

269 bone phenotype, we also observed an enhanced osteolytic response following RANKL injection over the c

270 Fbn2(-/-) mice display a greater than normal osteolytic response to locally implanted lipopolysacchar

271 y evoke heightened immune, inflammatory, and osteolytic responses that contribute to implant failure.

272 OC precursors, altering bone homeostasis and osteolytic responses.

273 immune and skeletal systems and suggests an osteolytic role of IL-12 in pathogenesis of periodontal

274 y-one days after intramedullary injection of osteolytic sarcoma cells into the femur, there was exten

275 Osteolytic sarcoma cells were implanted into the medulla

276 ation between predominantly osteoblastic and osteolytic spine metastases with a higher accuracy than

277 rentiation of predominantly osteoblastic and osteolytic spine metastases.

278 may provide a new molecular target for anti-osteolytic therapy.

279 at pad, as well as in bone protection in the osteolytic tibia.

280 genes may be relevant therapeutic targets in osteolytic tumor burden.

281 In vitro analyses revealed that osteolytic tumor cells lack expression of the Hh recepto

282 mor (GCT) of bone is a histologically benign osteolytic tumor featuring prominent osteoclast-like gia

283 her examination of the role of HTLV-1 Tax in osteolytic tumor formation and the development of hyperc

284 ncer pain, the hyperalgesia that occurs with osteolytic tumor growth is associated with the sensitiza

285 ilarly resistant to bone loss resulting from osteolytic tumor growth.

286 ased OC activity on tumor growth in 2 murine osteolytic tumor models.

287 angerhans Cell Histiocytosis (LCH), a benign osteolytic tumor-like disorder involving mainly the skel

288 tivity converted the C4-2B cells to a highly osteolytic tumor.

289 The osteolytic tumors in the 143B model showed the highest u

290 Expression of active Notch3 (NICD3) in osteolytic tumors reduced osteolytic lesion area and enh

291 g Tax (Tax(+)), which spontaneously develops osteolytic tumors throughout the vertebrae and hind limb

292 ferate rapidly, forming large, invasive, and osteolytic tumors when injected into mouse femurs, where

293 could effectively target metastasis to bone, osteolytic tumors, and soft tissue tumors.

294 human granzyme B promoter (Tax(+)), develop osteolytic tumors.

295 is a very rare, aggressive, and progressive osteolytic tumour for which no standard medicinal treatm

296 hoplasty was efficacious in the treatment of osteolytic vertebral compression fractures resulting fro

297 efficacy of kyphoplasty in the treatment of osteolytic vertebral compression fractures resulting fro

298 rocedures were performed in 18 patients with osteolytic vertebral compression fractures resulting fro

299 predominantly osteoblastic, 26 predominantly osteolytic) were detected.

300 PC3 and DU145 bone tumors were primarily osteolytic, whereas LNCaP bone tumors were both osteobla